List of Excipients in Branded Drug TAFLUPROST OPHTHALMIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	EDETATE DISODIUM
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	GLYCERIN
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	HYDROCHLORIC ACID
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	POLYSORBATE 80
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	SODIUM HYDROXIDE
Prasco Laboratories	TAFLUPROST OPHTHALMIC	tafluprost	66993-429	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE

Tafluprost Ophthalmic Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Tafluprost ophthalmic is a preservative-free prostaglandin analogue used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Its commercial opportunity is concentrated in formulation robustness, preservative-free delivery, unit-dose and multidose packaging, generic substitution, and differentiated combination products.

The reference product, marketed in the United States as Zioptan, contains tafluprost at 0.0015% in a sterile, preservative-free ophthalmic solution. The formulation uses a low-concentration active pharmaceutical ingredient, buffered aqueous vehicle, tonicity adjustment, surfactant, and chelating agent. Its low dose creates a narrow margin for excipient-driven changes in adsorption, degradation, droplet delivery, and container compatibility.[1]

What excipients are used in tafluprost ophthalmic products?

Tafluprost ophthalmic formulations generally use glycerol, phosphate buffer, polysorbate 80, edetate disodium, pH adjusters, and water for injection or purified water suitable for ophthalmic manufacture.

Formulation component	Typical function	Commercial and technical relevance
Tafluprost	Prostaglandin F2α analogue prodrug	Low-dose active requiring uniform delivery
Glycerol	Tonicity agent	Supports ocular tolerability and isotonicity
Sodium phosphate	Buffer	Controls pH and supports chemical stability
Polysorbate 80	Surfactant	Reduces adsorption and improves wetting
Edetate disodium	Chelating agent	Binds trace metals that can promote degradation
Hydrochloric acid or sodium hydroxide	pH adjustment	Controls stability, comfort, and preservative-free performance
Water	Vehicle	Must meet sterile ophthalmic quality requirements

The active concentration is approximately 15 micrograms per milliliter. At this concentration, small losses to the container, closure, dosing tip, or tubing can materially affect delivered dose. Excipient selection therefore has a direct relationship with bioequivalence and commercial viability.

How does tafluprost chemistry influence excipient selection?

Tafluprost is an ester prodrug that is converted in ocular tissues to its active acid. Formulation conditions must preserve the ester during manufacture and storage while allowing conversion after administration.

The principal formulation risks are:

1. Hydrolysis of the ester group.
2. Oxidative degradation.
3. Adsorption to polymeric surfaces.
4. Precipitation or loss of clarity.
5. Dose variability from low-concentration delivery.
6. Microbial contamination in preservative-free presentations.

A buffer system must control pH without accelerating hydrolysis. A surfactant such as polysorbate 80 can reduce surface adsorption, but it introduces its own risks, including peroxide formation, degradation products, and lot-to-lot variability. Edetate disodium can reduce metal-catalyzed degradation but may affect ocular tolerability at excessive concentrations.

The preferred excipient strategy is therefore a low-complexity formulation with tightly controlled raw materials, low peroxide surfactant grades, validated extractables and leachables data, and packaging selected for low active loss.

What is the reference formulation strategy for tafluprost ophthalmic?

The reference commercial strategy is preservative-free single-dose delivery. Zioptan is supplied in single-use containers rather than a conventional preserved multidose bottle.[1]

This design addresses the ocular-surface toxicity and intolerance associated with chronic exposure to preservatives such as benzalkonium chloride. It also creates higher packaging and manufacturing costs than preserved multidose products.

A reference formulation typically requires:

• Sterile filtration or aseptic manufacture.
• Single-use low-volume containers.
• Tight control of surfactant and chelator concentrations.
• Low adsorption packaging materials.
• Stability testing after opening or simulated dose withdrawal.
• Container-closure integrity testing.
• Control of particulate matter and visible defects.

The commercial trade-off is clear. Preservative-free delivery supports premium positioning and tolerability claims, but the unit-dose format increases material use, filling complexity, shipping volume, and patient-handling requirements.

What excipient strategies create commercial opportunities?

Preservative-free multidose delivery

The largest formulation opportunity is a preservative-free multidose bottle that maintains sterility without benzalkonium chloride. Such systems can reduce packaging waste and improve patient convenience compared with unit-dose containers.

The technical barrier is high. A multidose system must control microbial ingress while maintaining accurate dosing over the in-use period. A one-way valve, sterilizing filter, airless pump, or specialized dispensing tip may be required. The device becomes part of the product’s regulatory and intellectual-property strategy.

Alternative surfactant systems

Polysorbate 80 is effective but has known stability and peroxide concerns. Alternatives may include poloxamers, tyloxapol, polyoxyl castor-oil derivatives, or other ophthalmically acceptable nonionic surfactants.

The opportunity is not simply replacing polysorbate 80. A new surfactant system must demonstrate:

• Equivalent or improved tafluprost recovery.
• No increase in degradation products.
• Acceptable ocular comfort.
• Compatibility with the container and closure.
• No change in delivered dose.
• Comparable preservative-free microbiological performance.

A lower-peroxide surfactant platform could have value across multiple ophthalmic prostaglandins, including latanoprost, bimatoprost, travoprost, and tafluprost.

Buffer and pH optimization

A phosphate buffer is conventional, but citrate, borate, histidine, or mixed-buffer systems may provide different stability and comfort profiles. A lower-buffer-capacity formulation may reduce ocular irritation while still controlling pH during shelf life.

The strongest commercial position would come from a formulation that demonstrates improved stability without increasing excipient complexity. A simple pH-adjusted solution is easier to manufacture and defend against generic substitution than a formulation dependent on a complex excipient package.

Low-volume unit-dose systems

Unit-dose delivery remains commercially relevant for patients with ocular-surface disease, contact-lens intolerance, or sensitivity to preservatives. Opportunities include:

• Smaller polymer ampoules.
• Lower-fill-volume presentations.
• Easier-open packaging.
• Improved dose visibility.
• Recyclable or lower-material packaging.
• Calendarized adherence packs.

Packaging improvements can support device claims and create differentiation even where the solution composition is close to the reference product.

Combination ophthalmic products

Tafluprost could be paired with timolol, brimonidine, dorzolamide, or carbonic anhydrase inhibitors. Combination products could reduce dosing burden and improve adherence in patients requiring more than one mechanism of action.

The principal technical challenge is excipient compatibility. Different actives may require different pH ranges, buffers, tonicity agents, and preservatives. A preservative-free combination would have greater commercial value but also greater development complexity.

What formulations are protected by tafluprost patents?

Tafluprost intellectual property can include composition-of-matter claims, ophthalmic solution claims, preservative-free formulations, packaging systems, manufacturing processes, and methods of reducing intraocular pressure.

The most commercially relevant claim categories are:

Claim category	Potential commercial effect
Tafluprost molecule or stereoisomer	Broadest protection, generally first to expire
Ophthalmic solution composition	Can affect generic formulation design
Preservative-free formulation	May require design-around excipient selection
Container or delivery device	Can delay use of an identical presentation
Dosing or therapeutic method	May support method-of-use litigation
Manufacturing or impurity-control process	More relevant to supply-chain barriers

The original active-ingredient exclusivity for tafluprost in the United States has expired. Five-year new chemical entity exclusivity associated with the 2012 U.S. approval would have ended in 2017, subject to the precise regulatory exclusivity record.[1][2]

Patent protection must be analyzed separately from regulatory exclusivity. A generic applicant may challenge listed patents through an abbreviated new drug application and Paragraph IV certification. A formulation patent can remain commercially relevant after active-ingredient exclusivity ends, but its practical strength depends on claim scope, validity, infringement exposure, and whether a non-infringing formulation can obtain approval.

What is the Orange Book status of tafluprost ophthalmic?

Tafluprost ophthalmic is approved in the United States under NDA 202373. The Orange Book is the controlling source for current listed patents, exclusivity, therapeutic equivalence codes, and approved products.[1][2]

For commercial diligence, the relevant questions are:

• Whether the reference product has current patent listings.
• Whether any listed patents cover the solution, container, or method of use.
• Whether generic applicants have filed Paragraph IV certifications.
• Whether the product has an active therapeutic equivalence listing.
• Whether patent-listing disputes or delistings affect launch timing.

The main regulatory pathway for a conventional tafluprost generic is an ANDA demonstrating pharmaceutical equivalence and bioequivalence. A materially different delivery device, formulation, or clinical claim may require a 505(b)(2) application instead.

When does tafluprost lose exclusivity?

Tafluprost’s U.S. regulatory exclusivity has already expired. Market access is therefore governed primarily by patent status, ANDA review, product quality, and commercial supply capacity.

The timing framework is:

Milestone	Commercial significance
2012 FDA approval	Start of U.S. commercial exclusivity period
2017	Expected end of five-year NCE exclusivity
Post-2017	ANDA and Paragraph IV pathway available, subject to patents
Patent expiry	Depends on each listed patent and applicable extensions
Generic approval	Does not guarantee immediate commercial launch
Launch	May depend on litigation, settlement terms, and supply readiness

Exact generic-entry timing depends on the current Orange Book record and any patent litigation or settlement agreement. Regulatory exclusivity alone does not block current generic development.

Which companies are challenging tafluprost ophthalmic?

Tafluprost has been commercially relevant to Santen, Merck, Akorn, and other ophthalmic manufacturers through different periods and markets. The U.S. product and international products have not necessarily had the same sponsor, label, packaging, or intellectual-property position.

Publicly reported competitive activity should be evaluated through:

• FDA ANDA approvals.
• Orange Book therapeutic-equivalence listings.
• Paragraph IV litigation records.
• District court complaints.
• Abbreviated new drug application litigation notices.
• Product-label changes.
• Manufacturer supply and commercialization announcements.

A company can create effective competition without challenging every formulation patent if it uses a different excipient system, container, or method-of-use label.

What generic launch risks exist for tafluprost ophthalmic?

Generic launch risk is moderate to high in formulation and manufacturing, even after regulatory exclusivity ends.

Formulation risk

Tafluprost is present at very low concentration. Generic developers must control assay, impurities, degradation, and delivered dose near the lower analytical range. Small differences in surfactant grade, buffer strength, or container material can affect stability.

Device risk

A unit-dose container is easier to copy conceptually than a proprietary multidose delivery system, but the generic must still demonstrate dose uniformity, sterility, and container-closure integrity.

Bioequivalence risk

Topical ophthalmic bioequivalence may rely heavily on pharmaceutical equivalence, in vitro performance, comparative physicochemical characterization, and, where required, clinical or pharmacodynamic evidence. Differences in droplet size, viscosity, pH, osmolality, and dosing volume can create review risk.

Manufacturing risk

Preservative-free sterile ophthalmic manufacture requires specialized aseptic capacity. A developer without an established ophthalmic fill-finish network may face longer qualification timelines and higher batch-failure exposure.

How strong is the tafluprost patent estate?

The patent estate is strongest where claims cover a specific preservative-free composition, stability profile, device, or manufacturing process that is difficult to design around. It is weaker where protection depends on broad claims vulnerable to invalidity challenges or where generic developers can use different excipients.

A practical strength assessment should score:

Factor	Assessment
Active-ingredient exclusivity	Expired
Formulation differentiation	Potentially meaningful
Preservative-free claims	Commercially relevant if still enforceable
Device protection	Important for multidose systems
Design-around difficulty	Generally moderate
Manufacturing barriers	High for sterile preservative-free supply
Litigation leverage	Depends on current listed patents and claim construction

The strongest defensive strategy is usually a layered portfolio covering composition, container, manufacturing, and use. A single excipient claim is less durable if competitors can substitute another ophthalmically acceptable surfactant or buffer.

How does tafluprost compare with latanoprost and other prostaglandin analogues?

Product	Preservative-free opportunity	Formulation complexity	Commercial positioning
Tafluprost	High	High	Premium ocular-surface and preservative-free segment
Latanoprost	High	Moderate to high	Large generic base and established demand
Bimatoprost	Moderate to high	Moderate	Strong branded and generic competition
Travoprost	Moderate	Moderate	Preservative-free and multidose differentiation
Timolol combinations	High	High	Adherence and reduced dosing burden

Tafluprost’s commercial advantage is not volume alone. It is the ability to combine prostaglandin efficacy with preservative-free delivery. Its limitation is the smaller market and greater need for formulation and packaging differentiation against established generic prostaglandins.

What licensing opportunities exist for tafluprost excipient technology?

Licensing opportunities are most attractive in platform technologies that apply beyond tafluprost. Relevant assets include:

• Preservative-free multidose ophthalmic dispensers.
• Low-peroxide surfactant systems.
• Polymer surfaces that reduce adsorption.
• Stabilized prostaglandin formulations.
• Unit-dose packaging with lower material consumption.
• Aseptic filling and terminal sterilization alternatives.
• Combination products with improved pH compatibility.
• In-use stability systems that extend bottle life.

A license limited to tafluprost has a smaller addressable market. A platform applicable to tafluprost, latanoprost, bimatoprost, and travoprost is more commercially valuable because it can support several ANDA, 505(b)(2), or branded lifecycle programs.

What is the revenue exposure from tafluprost formulation improvements?

Revenue exposure is concentrated in three areas:

1. Premium preservative-free branded products.
2. Generic volume after patent and litigation barriers fall.
3. Technology licensing to ophthalmic manufacturers.

The largest value driver is likely a differentiated preservative-free multidose system that reduces cost per treated patient while preserving ocular-surface advantages. A new formulation that only changes buffer or tonicity may have limited pricing power unless it produces measurable improvements in stability, comfort, adherence, or shelf life.

Key Takeaways

• Tafluprost ophthalmic is a low-dose, preservative-free product with meaningful excipient and packaging sensitivity.
• Glycerol, phosphate buffer, polysorbate 80, and edetate disodium form the core reference-formulation strategy.
• The most attractive commercial opportunity is a preservative-free multidose delivery system.
• Surfactant replacement, low-peroxide excipients, adsorption control, and improved unit-dose packaging are credible development areas.
• U.S. regulatory exclusivity has expired, making current patent listings, Paragraph IV activity, and ANDA approvals the principal market-access issues.
• Formulation and sterile-manufacturing barriers remain important even after exclusivity expiration.
• Platform technology covering multiple prostaglandin analogues has greater licensing value than a tafluprost-only asset.

FAQs

Is tafluprost ophthalmic preservative-free?

Yes. The U.S. reference product Zioptan is supplied as a preservative-free ophthalmic solution in single-use containers.[1]

Can polysorbate 80 be replaced in tafluprost formulations?

Yes, but replacement requires evidence that the alternative surfactant maintains stability, dose uniformity, ocular tolerability, container compatibility, and bioequivalence-relevant performance.

Is tafluprost eligible for generic development?

Yes. Tafluprost is eligible for ANDA development, subject to the current Orange Book patent record, product-specific FDA requirements, and any litigation or settlement restrictions.

What is the most valuable tafluprost formulation innovation?

A preservative-free multidose system is likely to have the strongest commercial value because it could improve convenience and reduce packaging burden while preserving the reference product’s ocular-surface positioning.

Does tafluprost have biosimilar risk?

No. Tafluprost is a chemically synthesized small molecule, not a biologic. Competitive products enter through generic or 505(b)(2) pathways rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (2023). Zioptan: Tafluprost ophthalmic solution, 0.0015% prescribing information. NDA 202373.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. European Medicines Agency. (2024). Saflutan: EPAR product information. Amsterdam, Netherlands: European Medicines Agency.

4. United States Pharmacopeia. (2024). USP-NF: Ophthalmic preparations and pharmaceutical compounding standards. Rockville, MD: United States Pharmacopeial Convention.